MedTrace Logo

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 666

Last updated 2026-02-13

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.

Conditions

Interventions

DRUG

Verekitug

Verekitug (UPB-101) formulated solution

OTHER

Placebo

Matching Placebo to Verekitug (UPB-101)

Sponsors & Collaborators

  • Upstream Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Justin Salciccioli, MD · Upstream Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2028-04-30
Completion
2028-07-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Bulgaria
  • Chile
  • Czechia
  • Georgia
  • Germany
  • Hungary
  • India
  • Ireland
  • Latvia
  • Lithuania
  • Malaysia
  • Mexico
  • Philippines
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06981078 on ClinicalTrials.gov